Dottie Caplan, who previously served as Senior Vice President, Patient Advocacy and Engagement, will be responsible for leading Applied’s patient engagement and advocacy efforts as well as the ...

Sanofi acquired Genzyme for a little over $20 billion back in 2011. Genzyme has historically focused its efforts on rare inherited disorders, kidney diseases, cancer, transplant and immune disease ...

Eleven years after buying Genzyme, Sanofi officially ditches subsidiary’s storied name By Jonathan Saltzman Globe Staff,Updated February 3, 2022, 11:00 a.m.

W hen the French pharmaceutical giant Sanofi starts moving 2,500 employees from 10 sites in Massachusetts into a pair of new buildings in East Cambridge next month, visitors may notice something ...

A private equity firm is betting on an anticipated biomanufacturing boom, buying a Sanofi Genzyme distribution facility in Central Massachusetts. An affiliate of Wheelock Street Capital purchased ...

Fresh off its $11.6 billion acquisition of Waltham, Massachusetts-based Biogen spun-off, hemophilia drug developer Bioverativ, Sanofi has moved Genzyme from its old HQ to a brand new, 275,000 ...

Sanofi Genzyme will lay off 130 workers this week at its manufacturing plant in Boston in an effort to reduce costs and simplify operations, according to the Boston Globe.

Sanofi Genzyme, the Cambridge-based rare disease division of French drugmaker Sanofi SA (NYSE: SNY), has around 5,000 employees in Massachusetts. Despite the cuts, the company remains the largest ...

With some 5,000 workers in Massachusetts, Sanofi Genzyme continues to be the state’s largest employer in the life sciences industry. Genzyme received a $14.3 million grant from the Massachusetts ...

With some 5,000 workers in Massachusetts, Sanofi Genzyme continues to be the state’s largest employer in the life sciences industry. Genzyme received a $14.3 million grant from the Massachusetts ...

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold.